DLL3 and small cell lung carcinoma: SCLC-like transformation, often accompanied by TP53 and RB1 inactivation [85], necessitates therapeutic approaches informed by small cell lung cancer paradigms, including chemotherapy, PARP inhibitors, and DLL3-targeted antibody drug conjugates [86,87].